Probucol-poly(meth)acrylate-bile Acid Nanoparticles Increase IL-10, and Primary Bile Acids in Prediabetic Mice

References

• Hotamisligil GS . Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond.)32(7), 52–54 (2008).
   Google Scholar
• Mccarty MF . Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med. Hypotheses52(5), 465–477 (1999).
   PubMed Web of Science ®Google Scholar
• Van Greevenbroek MM , SchalkwijkCG , StehouwerCD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth. J. Med.71(4), 174–187 (2013).
   PubMed Web of Science ®Google Scholar
• Dahlen EM , TengbladA , LanneTet al. Abdominal obesity and low-grade systemic inflammation as markers of subclinical organ damage in type 2 diabetes. Diabetes Metab.40(1), 76–81 (2014).
   PubMed Web of Science ®Google Scholar
• Esser N , Legrand-PoelsS , PietteJ , ScheenAJ , PaquotN. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract.105(2), 141–150 (2014).
   PubMed Web of Science ®Google Scholar
• Pereira SS , Alvarez-LeiteJI. Low-grade inflammation, obesity, and diabetes. Curr. Obes. Rep.3(4), 422–431 (2014).
   PubMedGoogle Scholar
• Kuo SM , MerhigePM , HageyLR. The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10-/- mice. PLoS ONE8(3), e60270 (2013).
   PubMed Web of Science ®Google Scholar
• Vavassori P , MencarelliA , RengaB , DistruttiE , FiorucciS. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol.183(10), 6251–6261 (2009).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , Al-SallamiHSet al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech16(1), 45–52 (2015).
   PubMed Web of Science ®Google Scholar
• Mooranian A , ZamaniN , MikovMet al. Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Ther. Deliv.9(11), 811–821 (2018).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , TakechiR , MamoJ , Al-SallamiH , Al-SalamiH. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Transl. Res.8(3), 543–551 (2018).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , Al-SalamiH. Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of beta-cells. Ther. Deliv.7(3), 171–178 (2016).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , Al-SalamiH. The effects of ionic gelation- vibrational jet flow technique in fabrication of microcapsules incorporating β-cell: applications in diabetes. Curr. Diabetes Rev.13(1), 91–96 (2017).
   PubMed Web of Science ®Google Scholar
• Mooranian A , ZamaniN , TakechiRet al. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artif. Cells Nanomed. Biotechnol.1–7 (2018). doi:10.1080/21691401.2018.1511572 ( Epub ahead of print).
   Web of Science ®Google Scholar
• Mamo JC , LamV , Al-SalamiHet al. Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. Ther. Deliv.9(10), 703–709 (2018).
   PubMed Web of Science ®Google Scholar
• Takechi R , LamV , BrookEet al. Blood-brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link. Front. Aging Neurosci.9, 399 (2017).
   PubMed Web of Science ®Google Scholar
• Mamo JCL , LamV , GilesCet al. Antihypertensive agents do not prevent blood-brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. Int. J. Obes. (Lond.)41(6), 926–934 (2017).
   PubMed Web of Science ®Google Scholar
• Al-Salami H , MamoJC , MooranianAet al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exp. Clin. Endocrinol. Diabetes125(1), 28–32 (2017).
   PubMed Web of Science ®Google Scholar
• Al-Salami H , ButtG , TuckerI , MikovM. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find. Exp. Clin. Pharmacol.30(2), 107–113 (2008).
   PubMedGoogle Scholar
• Al-Salami H , ButtG , TuckerIet al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur. J. Drug Metab. Pharmacokinet.34(1), 43–50 (2009).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , TakechiR , MamoJC , Al-SallamiH , Al-SalamiH. The biological effects of the hypolipidaemic drug probucol incorporated into bile acid-microcapsules and fed daily for 4-weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv. Transl. Res.(2018) ( In press).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , ArfusoF , Al-SalamiH. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif. Cells Nanomed. Biotechnol.44(7), 1642–1653 (2016).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , Al-SalamiH , MorahanG , JamiesonE. Designing anti-diabetic beta-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: morphology, bioenergetics, and cytokine analysis. Biotechnol. Prog.32(2), 501–509 (2016).
   PubMed Web of Science ®Google Scholar
• Mooranian A , NegruljR , Al-SalamiH. The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. J. Microencapsul.33(6), 569–574 (2016).
   PubMed Web of Science ®Google Scholar
• Negrulj R , MooranianA , Al-SalamiH. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J. Endocrinol. Diabetes Mellitus.1(2), 49–59 (2013).
   Google Scholar
• Mooranian A , NegruljR , ArfusoF , Al-SalamiH. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv. Transl. Res.5(5), 511–522 (2015).
   PubMed Web of Science ®Google Scholar
• Qi Y , LohmanJ , BratlieKMet al. Vitamin C and B3 as new biomaterials to alter intestinal stem cells. J. Biomed. Mater. Res. A.107(9), 1886–1897 (2019).
   PubMed Web of Science ®Google Scholar
• Qi Y , ShiE , Peroutka-BigusNet al. Ex vivo study of telluride nanowires in minigut. J. Biomed. Nanotechnol.14(5), 978–986 (2018).
   PubMed Web of Science ®Google Scholar
• Chavez-Talavera O , TailleuxA , LefebvreP , StaelsB. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology152(7), 1679–1694 e1673 (2017).
   PubMed Web of Science ®Google Scholar
• Klisic A , IsakovicA , KocicGet al. Relationship between oxidative stress, inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes126(6), 371–378 (2018).
   PubMed Web of Science ®Google Scholar
• Davoudi Z , Peroutka-BigusN , BellaireBet al. Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases. J. Biomed. Mater. Res. A.106(4), 876–886 (2018).
   PubMed Web of Science ®Google Scholar
• Mikov M , BoniNS , Al-SalamiHet al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur. J. Drug Metab. Pharmacokinet.32(1), 7–12 (2007).
   PubMed Web of Science ®Google Scholar
• Dresner-Pollak R , GelbN , RachmilewitzD , KarmeliF , WeinrebM. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology127(3), 792–801 (2004).
   PubMed Web of Science ®Google Scholar
• Alizadeh BZ , Hanifi-MoghaddamP , EerlighPet al. Association of interferon-gamma and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clin. Exp. Immunol.145(3), 480–484 (2006).
   PubMed Web of Science ®Google Scholar
• Kolla VK , MadhaviG , PullaReddy Bet al. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine47(3), 173–177 (2009).
   PubMed Web of Science ®Google Scholar
• Banks WA , JaspanJB , KastinAJ. Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides18(10), 1577–1584 (1997).
   PubMed Web of Science ®Google Scholar
• Hajek T , CalkinC , BlagdonR , SlaneyC , UherR , AldaM. Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology39(12), 2910–2918 (2014).
   PubMed Web of Science ®Google Scholar
• Luu TH , BardJM , CarbonnelleDet al. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell Oncol. (Dordr)41(1), 13–24 (2018).
   PubMed Web of Science ®Google Scholar
• Du Q , ZhangY , PanY , DuanT. Lithocholic acid-induced placental tumor necrosis factor-alpha upregulation and syncytiotrophoblast cell apoptosis in intrahepatic cholestasis of pregnancy. Hepatol. Res.44(5), 532–541 (2014).
   PubMed Web of Science ®Google Scholar
• Holst JJ , McgillMA. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin. Drug Investig.32(1), 1–14 (2012).
   Web of Science ®Google Scholar
• Goldfine AB . Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr. Opin. Cardiol.23(5), 502–511 (2008).
   PubMed Web of Science ®Google Scholar
• Woodhams L , Al-SalamiH. The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. Ther. Deliv.8(6), 401–409 (2017).
   PubMedGoogle Scholar